CFCristina Filosa

Cristina Filosa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cristina Filosa has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    From 18F-MC225 to Conformationally Free Derivatives

    by Anna Teresa Lisi, Francesco Mastropasqua, Carmen Abate, Marialessandra Contino, Maria Grazia Perrone, Giovanni Graziano, Antonio Carrieri, Nicola Antonio Colabufo, Cristina Filosa, Maria Lucia Calcagni, et al.

    PET radiotracer [18F]MC225 is in two different clinical trials for imaging P-glycoprotein (P-gp) at the BBB level. This radiotracer permits to evaluate both the inset of neurodegenerative pathologies such as MCI, AD, and PD and the drug resistance of antidepressant drugs. Although these studies are ongoing, it is known that in MCI, AD, and PD the activity and expression of P-gp at the BBB level is lower than in healthy subjects, whereas the activity of the same pump is high in human subjects with resistance to antidepressant therapy. This level of P-gp is measured by PET with [18F]MC225 that displayed high brain uptake in neurodegenerative diseases and low brain uptake in subjects with resistance versus several antidepressant drugs. Starting from the mentioned PET radiotracer, a series of conformationally free derivatives have been synthesized testing the role of isosteric substitution in terms of P-gp interactions. Aryl-(oxy)-derivative 2c showed in vitro higher P-gp activity than MC225 (EC50 = 1.8 μM vs EC50 = 6.35 μM). This result has been corroborated with molecular docking, RMSD, and Rog timeline plot. The results disclosed a class of compounds, among them, 2c could be easily [11C]/[18F] radiolabeled for in vivo studies. Considering the lower lipophilicity of 2c than MC225, this ligand could be radiolabeled for imaging P-glycoprotein function and expression that is involved in several heart failures, where a low log P is an important and prelaminar parameter to drug targeting.

  • Open Access

    Designing a Small Molecule for PET Radiotracing: [18F]MC225 in Human Trials for Early Diagnosis in CNS Pathologies

    by Francesco Mastropasqua, Gert Luurtsema, Cristina Filosa, Nicola Antonio Colabufo

    P-Glycoprotein (P-gp, also known as MDR1 or ABCB1) is an ATP-binding cassette (ABC) transporter that actively effluxes a wide range of structurally and functionally diverse molecules, playing a crucial role in drug absorption, distribution, and excretion. P-gp is highly expressed at key biological barriers, such as the blood–brain barrier (BBB), intestine, liver, and kidneys, and it serves as a gatekeeper against xenobiotics and therapeutics. Its dysregulation is involved in multidrug resistance (MDR), epilepsy, cancer, infectious diseases, and neurodegenerative disorders. Several small molecules were synthesized using SAfIR and SAR, and, among them, [18F]MC225 showed the most promising results for in vivo human studies, with appropriate pharmacodynamics and pharmacokinetics profiles for in vivo use. [18F]MC225 is currently being employed in PHASE II human trials at the UMC Groningen, the Netherlands, in patients diagnosed with AD, PD and MCI, as well as PHASE II human trials at the Policlinico Gemelli in Rome Italy to diagnose P-gp resistant depression. Preliminary studies show that [18F]MC225 radiotracer is behaving according to the initial predictions, that is, it accurately diagnoses the aforementioned pathologies, more so than previously developed small molecules for the same goal.


  • Cyclophosphamide and Etoposide: A mathematical evaluation of the decay of two highly reactive molecules

    by Cristina Filosa, Nicola Antonio Colabufo, Marcello Leopoldo, Donatella Telesca, Maria Rita Milella, Carmela Mazzoccoli, Alfredo Tartarone, Antonio Prospero Colasurdo, Rosa Lerose

    Cyclophosphamide and Etoposide are two antineoplastic drugs that are commonly employed in the treatment of several types of cancer, including prostate, stomach, and lung cancer, as well as multiple myeloma and sarcoma. The course of treatment often involves a mixture of etoposide and cyclophosphamide with other molecules, such as cisplatin for the former, or dactinomycin and vincristine for the latter. In this study, two separate analytical methods are proposed to evaluate the stability and the decay of Cyclophosphamide and Etoposide solutions prepared in normal saline and glucose (5%). The solutions of each antineoplastic drug were prepared by the IRCCS CROB RIONERO at three separate dosages and were submitted to HPLC-UV apparatus for the analysis. Firstly, two calibration curves were carried out to validate the method; secondly, samples of each solution were taken at specific time points to evaluate the decay in concentration of the molecules. The results show a stark decrease in stability of etoposide at increasing drug concentrations. On the other hand, cyclophosphamide is known for being highly unstable after reconstitution, therefore its decay was expected at each dosage. The data obtained by the triplicate analysis of both drugs at each time point was then used to mathematically evaluate the decay pattern of each molecule.